Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Gynecology

  Free Subscription


Articles published in Cancer

Retrieve available abstracts of 93 articles:
HTML format
Text format



Single Articles


    January 2018
  1. RAZZAGHI H, Saraiya M, Thompson TD, Henley SJ, et al
    Five-year relative survival for human papillomavirus-associated cancer sites.
    Cancer. 2018;124:203-211.
    PubMed     Text format     Abstract available


    December 2017
  2. STEWART SL, Harewood R, Matz M, Rim SH, et al
    Disparities in ovarian cancer survival in the United States (2001-2009): Findings from the CONCORD-2 study.
    Cancer. 2017;123 Suppl 24:5138-5159.
    PubMed     Text format     Abstract available


  3. BENARD VB, Watson M, Saraiya M, Harewood R, et al
    Cervical cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study.
    Cancer. 2017;123 Suppl 24:5119-5137.
    PubMed     Text format     Abstract available


  4. TAARNHOJ GA, Christensen IJ, Lajer H, Fuglsang K, et al
    Risk of recurrence, prognosis, and follow-up for Danish women with cervical cancer in 2005-2013: A national cohort study.
    Cancer. 2017 Dec 6. doi: 10.1002/cncr.31165.
    PubMed     Text format     Abstract available


  5. GROEN R, Abe K, Yoon HS, Li Z, et al
    Application of microscope-based scanning software (Panoptiq) for the interpretation of cervicovaginal cytology specimens.
    Cancer. 2017;125:918-925.
    PubMed     Text format     Abstract available


    November 2017
  6. PRINTZ C
    Large population study quantifies chances of pregnancy after cancer treatment.
    Cancer. 2017;123:4308.
    PubMed     Text format    


  7. LUTGENDORF SK, Thaker PH, Arevalo JM, Goodheart MJ, et al
    Biobehavioral modulation of the exosome transcriptome in ovarian carcinoma.
    Cancer. 2017 Nov 7. doi: 10.1002/cncr.31078.
    PubMed     Text format     Abstract available


    October 2017
  8. CHAD-FRIEDMAN E, Coleman S, Traeger LN, Pirl WF, et al
    Psychological distress associated with cancer screening: A systematic review.
    Cancer. 2017;123:3882-3894.
    PubMed     Text format     Abstract available


  9. NELSON RA, Lai LL
    Elevated risk of human papillomavirus-related second cancers in survivors of anal canal cancer.
    Cancer. 2017;123:4013-4021.
    PubMed     Text format     Abstract available


    September 2017
  10. LE GALLO M, Rudd ML, Urick ME, Hansen NF, et al
    The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.
    Cancer. 2017 Sep 21. doi: 10.1002/cncr.30971.
    PubMed     Text format     Abstract available


  11. TAO X, Austin RM, Zhang H, Zhang L, et al
    Histopathologic follow-up and HPV test results with HSIL Papanicolaou test results in China's largest academic women's hospital.
    Cancer. 2017 Sep 8. doi: 10.1002/cncy.21914.
    PubMed     Text format     Abstract available


  12. BOBER SL, Recklitis CJ, Michaud AL, Wright AA, et al
    Improvement in sexual function after ovarian cancer: Effects of sexual therapy and rehabilitation after treatment for ovarian cancer.
    Cancer. 2017 Sep 7. doi: 10.1002/cncr.30976.
    PubMed     Text format     Abstract available


  13. PRINJA S, Bahuguna P, Faujdar DS, Jyani G, et al
    Cost-effectiveness of human papillomavirus vaccination for adolescent girls in Punjab state: Implications for India's universal immunization program.
    Cancer. 2017;123:3253-3260.
    PubMed     Text format     Abstract available


    August 2017
  14. ZHOU AG, Levinson KL, Rosenthal DL, VandenBussche CJ, et al
    Performance of ovarian cyst fluid fine-needle aspiration cytology.
    Cancer. 2017 Aug 21. doi: 10.1002/cncy.21911.
    PubMed     Text format     Abstract available


  15. TRACHT JM, Davis AD, Fasciano DN, Eltoum IA, et al
    Discrepant HPV/cytology cotesting results: Are there differences between cytology-negative versus HPV-negative cervical intraepithelial neoplasia?
    Cancer. 2017 Aug 17. doi: 10.1002/cncy.21905.
    PubMed     Text format     Abstract available


  16. MOORE KN, Borghaei H, O'Malley DM, Jeong W, et al
    Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in patients with solid tumors.
    Cancer. 2017;123:3080-3087.
    PubMed     Text format     Abstract available


  17. HUNG YP, Lovitch SB, Qian X
    Histiocytic sarcoma: New insights into FNA cytomorphology and molecular characteristics.
    Cancer. 2017;125:604-614.
    PubMed     Text format     Abstract available


    July 2017
  18. EVERETT EN
    The evolving role of cytopathology in the era of neoadjuvant chemotherapy for the accurate pathologic diagnosis of epithelial ovarian cancer.
    Cancer. 2017 Jul 31. doi: 10.1002/cncy.21894.
    PubMed     Text format    


  19. TOMAO F, D'Incalci M, Biagioli E, Peccatori FA, et al
    Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum-free interval: Myth or reality?
    Cancer. 2017 Jul 5. doi: 10.1002/cncr.30830.
    PubMed     Text format     Abstract available


  20. PRINTZ C
    Expert panel issues new global cervical cancer screening guideline.
    Cancer. 2017;123:2387-2388.
    PubMed     Text format    


  21. LEWIS DR, Chen HS, Cockburn MG, Wu XC, et al
    Early estimates of SEER cancer incidence, 2014.
    Cancer. 2017;123:2524-2534.
    PubMed     Text format     Abstract available


  22. KOPP RP, Stratton KL, Glogowski E, Schrader KA, et al
    Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma.
    Cancer. 2017;123:2452-2458.
    PubMed     Text format     Abstract available


    June 2017
  23. BATEMAN NW, Dubil EA, Wang G, Hood BL, et al
    Race-specific molecular alterations correlate with differential outcomes for black and white endometrioid endometrial cancer patients.
    Cancer. 2017 Jun 27. doi: 10.1002/cncr.30813.
    PubMed     Text format     Abstract available


  24. WALTERHOUSE DO, Pappo AS, Meza JL, Breneman JC, et al
    Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Cancer. 2017;123:2368-2375.
    PubMed     Text format     Abstract available


  25. GE Y, Christensen P, Luna E, Armylagos D, et al
    Performance of Aptima and Cobas HPV testing platforms in detecting high-grade cervical dysplasia and cancer.
    Cancer. 2017 Jun 2. doi: 10.1002/cncy.21875.
    PubMed     Text format     Abstract available


  26. RIMAR KJ, Tran PT, Matulewicz RS, Hussain M, et al
    The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
    Cancer. 2017;123:1912-1924.
    PubMed     Text format     Abstract available


    May 2017
  27. KOROUKIAN SM, Bakaki PM, Htoo PT, Han X, et al
    The Breast and Cervical Cancer Early Detection Program, Medicaid, and breast cancer outcomes among Ohio's underserved women.
    Cancer. 2017 May 23. doi: 10.1002/cncr.30720.
    PubMed     Text format     Abstract available


  28. SCALICI JM, Arapovic S, Saks EJ, Atkins KA, et al
    Mesothelium expression of vascular cell adhesion molecule-1 (VCAM-1) is associated with an unfavorable prognosis in epithelial ovarian cancer (EOC).
    Cancer. 2017;123:977-984.
    PubMed     Text format     Abstract available


  29. LONG ROCHE KC, Abu-Rustum NR, Nourmoussavi M, Zivanovic O, et al
    Risk-reducing salpingectomy: Let us be opportunistic.
    Cancer. 2017;123:1714-1720.
    PubMed     Text format     Abstract available


  30. FRICK MA, Vachani CC, Hampshire MK, Bach C, et al
    Survivorship after lower gastrointestinal cancer: Patient-reported outcomes and planning for care.
    Cancer. 2017;123:1860-1868.
    PubMed     Text format     Abstract available


  31. BALASUBRAMANIAM S, Kim GS, McKee AE, Pazdur R, et al
    Regulatory considerations on endpoints in ovarian cancer drug development.
    Cancer. 2017 May 12. doi: 10.1002/cncr.30652.
    PubMed     Text format     Abstract available


  32. IVY SP, Kohn EC
    Drug development and registration: Challenges and opportunities in ovarian cancer.
    Cancer. 2017 May 12. doi: 10.1002/cncr.30645.
    PubMed     Text format    


  33. GUO M, Khanna A, Wang J, Dawlett MA, et al
    Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening.
    Cancer. 2017 May 12. doi: 10.1002/cncy.21877.
    PubMed     Text format     Abstract available


  34. HUANG GS, Santin AD
    Genetic landscape of clear cell endometrial cancer and the era of precision medicine.
    Cancer. 2017 May 9. doi: 10.1002/cncr.30743.
    PubMed     Text format    


  35. LE GALLO M, Rudd ML, Urick ME, Hansen NF, et al
    Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing.
    Cancer. 2017 May 9. doi: 10.1002/cncr.30745.
    PubMed     Text format     Abstract available


  36. SMALL W JR, Bacon MA, Bajaj A, Chuang LT, et al
    Cervical cancer: A global health crisis.
    Cancer. 2017 May 2. doi: 10.1002/cncr.30667.
    PubMed     Text format     Abstract available


  37. STOPECK AT
    Osteoclast inhibition in postmenopausal breast cancer: Is the evidence too strong to ignore?
    Cancer. 2017 May 2. doi: 10.1002/cncr.30678.
    PubMed     Text format    


  38. LIPTON A, Chapman JW, Leitzel K, Garg A, et al
    Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27.
    Cancer. 2017 May 2. doi: 10.1002/cncr.30682.
    PubMed     Text format     Abstract available


  39. ZENNARO L, Vanzani P, Nicole L, Cappellesso R, et al
    Metabonomics by proton nuclear magnetic resonance in human pleural effusions: A route to discriminate between benign and malignant pleural effusions and to target small molecules as potential cancer biomarkers.
    Cancer. 2017;125:341-348.
    PubMed     Text format     Abstract available


    April 2017
  40. BEN-AMI E, Barysauskas CM, Solomon S, Tahlil K, et al
    Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study.
    Cancer. 2017 Apr 25. doi: 10.1002/cncr.30738.
    PubMed     Text format     Abstract available


  41. PRINTZ C
    New treatment for patients with advanced ovarian cancer receives accelerated approval.
    Cancer. 2017;123:1286-1287.
    PubMed     Text format    


  42. ALSBEIH GA, Al-Harbi NM, Bin Judia SS, Khoja HA, et al
    Reduced rate of human papillomavirus infection and genetic overtransmission of TP53 72C polymorphic variant lower cervical cancer incidence.
    Cancer. 2017 Apr 10. doi: 10.1002/cncr.30635.
    PubMed     Text format     Abstract available


  43. LIANG X, Margolis KL, Hendryx M, Reeves K, et al
    Effect of depression before breast cancer diagnosis on mortality among postmenopausal women.
    Cancer. 2017 Apr 7. doi: 10.1002/cncr.30688.
    PubMed     Text format     Abstract available


    March 2017
  44. QUINN AM, Minhajuddin AT, Hynan LS, Reisch JS, et al
    Agreement between cytotechnologists and cytopathologists as a new measure of cytopathologist performance in gynecologic cytology.
    Cancer. 2017 Mar 27. doi: 10.1002/cncy.21856.
    PubMed     Text format     Abstract available


  45. BERMAN TA, Schiller JT
    Human papillomavirus in cervical cancer and oropharyngeal cancer: One cause, two diseases.
    Cancer. 2017 Mar 27. doi: 10.1002/cncr.30588.
    PubMed     Text format     Abstract available


  46. STARK DP, Cook A, Brown JM, Brundage MD, et al
    Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial.
    Cancer. 2017 Mar 24. doi: 10.1002/cncr.30657.
    PubMed     Text format     Abstract available


  47. SAMIMI G, Minasian LM
    Opportunistic salpingectomy: What about the role of the ovary in ovarian cancer?
    Cancer. 2017 Mar 23. doi: 10.1002/cncr.30525.
    PubMed     Text format    


  48. KALINSKY K, Lee S, Rubin KM, Lawrence DP, et al
    A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607).
    Cancer. 2017 Mar 23. doi: 10.1002/cncr.30663.
    PubMed     Text format     Abstract available


  49. STIEKEMA A, Van de Vijver KK, Boot H, Broeks A, et al
    Human epididymis protein 4 immunostaining of malignant ascites differentiates cancer of Mullerian origin from gastrointestinal cancer.
    Cancer. 2017;125:197-204.
    PubMed     Text format     Abstract available


  50. BENEVOLO M, Allia E, Gustinucci D, Rollo F, et al
    Interobserver reproducibility of cytologic p16INK4a /Ki-67 dual immunostaining in human papillomavirus-positive women.
    Cancer. 2017;125:212-220.
    PubMed     Text format     Abstract available


    February 2017
  51. ZANET E, Ciancia R, Michieli M, Tirelli U, et al
    "Twistin' the night away": Fertility preservation in young adult female cancer survivors.
    Cancer. 2017;123:707-708.
    PubMed     Text format    


  52. BENEDICT C, Thom B, Friedman DN, Diotallevi D, et al
    Reply to "Twistin' the night away": Fertility preservation in young adult female cancer survivors.
    Cancer. 2017;123:708-709.
    PubMed     Text format    


  53. CRAGUN D, Weidner A, Lewis C, Bonner D, et al
    Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors.
    Cancer. 2017 Feb 9. doi: 10.1002/cncr.30621.
    PubMed     Text format     Abstract available


  54. JACKSON SE, Steptoe A, Fisher A
    Reply to Sexual quality of life in the cancer continuum.
    Cancer. 2017;123:530-531.
    PubMed     Text format    


    January 2017
  55. BRAR H, Hogen L, Covens A
    Cost-effectiveness of sentinel node biopsy and pathological ultrastaging in patients with early-stage cervical cancer.
    Cancer. 2017 Jan 24. doi: 10.1002/cncr.30509.
    PubMed     Text format     Abstract available


  56. BEAVIS AL, Gravitt PE, Rositch AF
    Hysterectomy-corrected cervical cancer mortality rates reveal a larger racial disparity in the United States.
    Cancer. 2017 Jan 23. doi: 10.1002/cncr.30507.
    PubMed     Text format     Abstract available


  57. DALTON HJ, Farley JH
    Racial disparities in cervical cancer: Worse than we thought.
    Cancer. 2017 Jan 23. doi: 10.1002/cncr.30501.
    PubMed     Text format    


  58. BUYS SS, Sandbach JF, Gammon A, Patel G, et al
    A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
    Cancer. 2017 Jan 13. doi: 10.1002/cncr.30498.
    PubMed     Text format     Abstract available


  59. TALHOUK A, McConechy MK, Leung S, Yang W, et al
    Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.
    Cancer. 2017 Jan 6. doi: 10.1002/cncr.30496.
    PubMed     Text format     Abstract available


  60. MILLER DS
    Patients with endometrial cancer at risk for lymphatic metastasis should undergo pelvic and periaortic lymphadenectomy as part of their initial surgery.
    Cancer. 2017;123:192-196.
    PubMed     Text format    


  61. KANG S, Nam JH, Bae DS, Kim JW, et al
    Preoperative assessment of lymph node metastasis in endometrial cancer: A Korean Gynecologic Oncology Group study.
    Cancer. 2017;123:263-272.
    PubMed     Text format     Abstract available


  62. HURTEAU JA
    Omitting lymphadenectomy in patients with endometrial cancer.
    Cancer. 2017;123:197-199.
    PubMed     Text format    


    December 2016
  63. GREENWALD ZR, Huang LN, Wissing MD, Franco EL, et al
    Does hormonal therapy for fertility preservation affect the survival of young women with early-stage endometrial cancer?
    Cancer. 2016 Dec 27. doi: 10.1002/cncr.30529.
    PubMed     Text format     Abstract available


  64. HOU JY, Baptiste C, Hombalegowda RB, Tergas AI, et al
    Vulvar and vaginal melanoma: A unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma.
    Cancer. 2016 Dec 27. doi: 10.1002/cncr.30473.
    PubMed     Text format     Abstract available


  65. WINDER AD, Maniar KP, Wei JJ, Liu D, et al
    Synuclein-gamma in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study.
    Cancer. 2016 Dec 7. doi: 10.1002/cncr.30477.
    PubMed     Text format     Abstract available


  66. OVESTAD IT, Dalen I, Hansen E, Loge JL, et al
    Clinical value of fully automated p16/Ki-67 dual staining in the triage of HPV-positive women in the Norwegian Cervical Cancer Screening Program.
    Cancer. 2016 Dec 5. doi: 10.1002/cncy.21807.
    PubMed     Text format     Abstract available


  67. GULATI R, Albertsen PC
    Insights from the PLCO trial about prostate cancer screening.
    Cancer. 2016 Dec 1. doi: 10.1002/cncr.30472.
    PubMed     Text format    


    November 2016
  68. GANESH K, Shah RH, Vakiani E, Nash GM, et al
    Clinical and genetic determinants of ovarian metastases from colorectal cancer.
    Cancer. 2016 Nov 22. doi: 10.1002/cncr.30424.
    PubMed     Text format     Abstract available


  69. FANG CY, Ma GX, Handorf EA, Feng Z, et al
    Addressing multilevel barriers to cervical cancer screening in Korean American women: A randomized trial of a community-based intervention.
    Cancer. 2016 Nov 21. doi: 10.1002/cncr.30391.
    PubMed     Text format     Abstract available


  70. RUNGRUANG BJ, Miller A, Krivak TC, Horowitz NS, et al
    What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study.
    Cancer. 2016 Nov 16. doi: 10.1002/cncr.30414.
    PubMed     Text format     Abstract available


    October 2016
  71. THOMPSON B, Carosso EA, Jhingan E, Wang L, et al
    Results of a randomized controlled trial to increase cervical cancer screening among rural Latinas.
    Cancer. 2016 Oct 27. doi: 10.1002/cncr.30399.
    PubMed     Text format     Abstract available


  72. PATADJI S, Li Z, Pradhan D, Zhao C, et al
    Significance of high-risk HPV detection in women with atypical glandular cells on Pap testing: Analysis of 1857 cases from an academic institution.
    Cancer. 2016 Oct 24. doi: 10.1002/cncy.21791.
    PubMed     Text format     Abstract available


  73. LI Y, Zeng J, Huang M, An J, et al
    A phase 2 study of nanoparticle albumin-bound paclitaxel plus nedaplatin for patients with advanced, recurrent, or metastatic cervical carcinoma.
    Cancer. 2016 Oct 3. doi: 10.1002/cncr.30328.
    PubMed     Text format     Abstract available


    September 2016
  74. SILVER MI, Schiffman M, Fetterman B, Poitras NE, et al
    The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen.
    Cancer. 2016 Sep 22. doi: 10.1002/cncr.30277.
    PubMed     Text format     Abstract available


  75. HUH WK, Andrews JC
    Cervical cancer screening: How do we make sense of it all and what is the right balance?
    Cancer. 2016 Sep 22. doi: 10.1002/cncr.30276.
    PubMed     Text format    


  76. RAO P, Li Y, Getz KD, Miller TP, et al
    Low rates of pregnancy screening in adolescents before teratogenic exposures in a national sample of children's hospitals.
    Cancer. 2016 Sep 12. doi: 10.1002/cncr.30225.
    PubMed     Text format     Abstract available


  77. MAKKER V, Recio FO, Ma L, Matulonis UA, et al
    A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study).
    Cancer. 2016 Sep 7. doi: 10.1002/cncr.30286.
    PubMed     Text format     Abstract available


  78. MUTCH DG
    Targeted therapy in endometrial cancer: Making progress.
    Cancer. 2016 Sep 7. doi: 10.1002/cncr.30285.
    PubMed     Text format    


    August 2016
  79. RYDZEWSKI NR, Strohl AE, Donnelly ED, Kanis MJ, et al
    Receipt of vaginal brachytherapy is associated with improved survival in women with stage I endometrioid adenocarcinoma of the uterus: A National Cancer Data Base study.
    Cancer. 2016 Aug 10. doi: 10.1002/cncr.30228.
    PubMed     Text format     Abstract available


    July 2016
  80. DRESCHER CW, Beatty JD, Resta R, Andersen MR, et al
    The effect of referral for genetic counseling on genetic testing and surgical prevention in women at high risk for ovarian cancer: Results from a randomized controlled trial.
    Cancer. 2016 Jul 22. doi: 10.1002/cncr.30190.
    PubMed     Text format     Abstract available


  81. DEL CARMEN MG, Supko JG, Horick NK, Rauh-Hain JA, et al
    Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.
    Cancer. 2016 Jul 15. doi: 10.1002/cncr.30196.
    PubMed     Text format     Abstract available


    June 2016
  82. LEREBOURS F, Rivera S, Mouret-Reynier MA, Alran S, et al
    Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French t
    Cancer. 2016 Jun 17. doi: 10.1002/cncr.30143.
    PubMed     Text format     Abstract available


  83. MCALPINE JN, Temkin SM, Mackay HJ
    Endometrial cancer: Not your grandmother's cancer.
    Cancer. 2016 Jun 16. doi: 10.1002/cncr.30094.
    PubMed     Text format     Abstract available


  84. GEYER HL, Andreasson B, Kosiorek HE, Dueck AC, et al
    The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group.
    Cancer. 2016;122:1888-96.
    PubMed     Text format     Abstract available


  85. GUINDALINI RS, Song A, Fackenthal JD, Olopade OI, et al
    Genetic anticipation in BRCA1/BRCA2 families after controlling for ascertainment bias and cohort effect.
    Cancer. 2016;122:1913-20.
    PubMed     Text format     Abstract available


    May 2016
  86. WHOP LJ, Garvey G, Baade P, Cunningham J, et al
    The first comprehensive report on Indigenous Australian women's inequalities in cervical screening: A retrospective registry cohort study in Queensland, Australia (2000-2011).
    Cancer. 2016;122:1560-9.
    PubMed     Text format     Abstract available


  87. LIAO ZW, Rodrigues MC, Poynter JN, Amatruda JF, et al
    Risk of second gonadal cancers in women and children with germ cell tumors.
    Cancer. 2016 May 6. doi: 10.1002/cncr.30014.
    PubMed     Text format     Abstract available


  88. REUSCHENBACH M, Pauligk C, Karbach J, Rafiyan MR, et al
    A phase 1/2a study to test the safety and immunogenicity of a p16(INK4a) peptide vaccine in patients with advanced human papillomavirus-associated cancers.
    Cancer. 2016;122:1425-33.
    PubMed     Text format     Abstract available


    April 2016
  89. PRINTZ C
    BRCA 1/2-negative patients who receive counseling after genetic testing have lower anxiety.
    Cancer. 2016;122:1149.
    PubMed     Text format    


    March 2016
  90. WRIGHT BJ, Conlin AK, Allen HL, Tsui J, et al
    What does Medicaid expansion mean for cancer screening and prevention? Results from a randomized trial on the impacts of acquiring Medicaid coverage.
    Cancer. 2016;122:791-7.
    PubMed     Text format     Abstract available


    February 2016
  91. ARMSTRONG K, Kim JJ, Halm EA, Ballard RM, et al
    Using lessons from breast, cervical, and colorectal cancer screening to inform the development of lung cancer screening programs.
    Cancer. 2016 Feb 29. doi: 10.1002/cncr.29937.
    PubMed     Text format     Abstract available


    January 2016
  92. WALSH CS
    The more you look, the more you will find.
    Cancer. 2016;122:14-6.
    PubMed     Text format    


    October 2015
  93. HURTEAU JA, Febbraro T
    Germ cell tumors: Treatment consensus across all age groups through MaGIC [Malignant Germ Cell International Collaborative].
    Cancer. 2015 Oct 20. doi: 10.1002/cncr.29729.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: